Month: September 2020

Victory Square Technologies Portfolio Company Receives Approval for Sale and Use of Safetest Covid-19 Antibody Test for the European Union

Written by Customer Service on September 14, 2020. Posted in Public Companies.

Victory Square Health received CE from EU competent authority of Belgium for Safetest ELISA antibody test for distribution, sale, and usage in the European UnionSafetest Covid-19™ test enables the user to verify whether they are currently infected, have been infected or have never been infected with Covid-19This approval now enables Victory Square Health to distribute throughout the 27 countries and 446M inhabitants which make up the European UnionVictory Square Health received FDA permission to sell and market on August 14 and received Anvisa approval for Sale & Use of Safetest Covid-19 Antibody Test for the Country of Brazil on September 8.VANCOUVER, British Columbia, Sept. 14, 2020 (GLOBE NEWSWIRE) — Victory Square Health Inc. (“VS Health” or the “Company“) – a portfolio company of Victory Square Technologies...

Mexus Readies Ball Mill to Recover High Grade Gold

Written by Customer Service on September 14, 2020. Posted in Public Companies.

CABORCA, Mexico, Sept. 14, 2020 (GLOBE NEWSWIRE) — Mexus Gold US (OTCQB: MXSG) (“Mexus” or the “Company) announced that it is nearing the completion and test running of its high grade ball mill gravity gold recovery system. As stated previously, this coincides with the development of the quartz vein systems at the Santa Elena mine in Caborca, MX. Mexus has developed a plan targeting the high-grade quartz vein as part of the Julio system. An average cutoff grade of .10 Gpt Au will be milled and recovered by the gravity system with lower grades continuing to be placed on the heap leach pad. New photos added to websiteAbout Mexus Gold USMexus Gold US is an American based mining company with holdings in Mexico. The fully owned Santa Elena mine is located 54km NW of Caborca, Mexico. Mexus also owns rights to the Ures property...

Exercise of warrants in Better Collective A/S; Board of Directors issues 57,460 new ordinary shares

Written by Customer Service on September 14, 2020. Posted in Public Companies.

Regulatory Release 35/2020In the exercise window which opened on August 25, 2020 following Better Collective’s Q2 report and closed on September 8, 2020, 14 employees have informed the company that they wish to exercise in total 57,460 warrants under the 2017 warrant program.The 2017 warrant program was established prior to the company’s IPO and the warrants were issued in 2017 and 2018. Reference is made to schedule 2 of the company’s articles of association for detailed terms of conditions of the warrants.As of September 8, 2020, 826,794 warrants remain outstanding (excluding the warrants exercised following the Q2 report) under the 2017 warrant program, all with rights to subscribe for 1 ordinary share in Better Collective A/S against payment of an exercise price of DKK 12.962962 per warrant.Today Better Collective’s board of directors...

Euro Sun Provides Corporate Update

Written by Customer Service on September 14, 2020. Posted in Public Companies.

TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) — Euro Sun Mining Inc. (TSX: ESM) (“Euro Sun” or the “Company”) is pleased to provide a corporate update and comment on the current strategy regarding development of the ten million gold equivalent ounce Rovina Valley Project.In response to many questions from shareholders, we would like to provide an update on recent developments at the Rovina Valley Project so that all investors have a clear understanding of the ultimate value of this world class gold development project.The last two quarters have seen significant progress towards a construction decision for the Rovina Valley Project with ongoing work on the construction permit and related activities around the process. In addition, the definitive feasibility study, being completed by Senet Pty, continues to progress. In June, the Company...

Oxurion NV to Present at H.C. Wainwright & Co 22nd Annual Global Investment Conference

Written by Customer Service on September 14, 2020. Posted in Public Companies.

Oxurion NV to Present at H.C. Wainwright & Co22nd Annual Global Investment Conference Leuven, Belgium , 14 September 2020 – 8.00 A.M. CET – Oxurion NV (Euronext Bxls: OXUR), a biopharmaceutical company developing next generation standard-of-care therapies for diabetic macular edema (DME), announces today that the Company’s CEO, Dr.Patrik De Haes, will be presenting at HC Wainwright & Co’s 22nd Annual Global Investment Conference on Wednesday, September 16th, 2020 at 10:00 a.m. ET.The presentation will cover Oxurion’s emerging DME franchise designed to improve the treatment outcomes of all DME patients. The Company’s franchise is based around THR-149 and THR-687, two novel drug candidates with different, non-VGEF modes of action. DME is a significant global healthcare problem and the major cause of vision loss...

Wolters Kluwer to Acquire XCM Solutions

Written by Customer Service on September 14, 2020. Posted in Public Companies.

Wolters Kluwer to Acquire XCM SolutionsSeptember 14, 2020 – Wolters Kluwer Tax & Accounting announces today that it has entered into an agreement to acquire XCM Solutions, a cloud-based workflow solutions provider for professional tax and accounting firms. The acquisition offers integration opportunities with CCH® Axcess™, our cloud-based software suite for professional firms in North America.Wolters Kluwer Tax & Accounting North America has had a longstanding strategic partnership with XCM Solutions since 2006, enabling firms to integrate XCM workflow tools with CCH® ProSystem fx® on-premise software and, since 2012, with CCH Axcess, our cloud-based, modular software platform. Wolters Kluwer and XCM share a common approach to providing innovative, cloud-based solutions that drive productivity for customers.Founded in 2002,...

Euronext statement regarding Borsa Italiana

Written by Customer Service on September 14, 2020. Posted in Mergers And Acquisitions.

EURONEXT STATEMENT REGARDING BORSA ITALIANAAmsterdam, Brussels, Dublin, Lisbon, Oslo and Paris – 14 September 2020 – Euronext confirms the submission of a non-binding offer to London Stock Exchange Group plc to acquire Borsa Italiana. The partnership includes CDP Equity and Intesa Sanpaolo. There can be no certainty that this will lead to a transaction.The proposed combination of Borsa Italiana and Euronext would create a leading player in continental European capital markets, where Italy would be the largest revenue contributor to the enlarged Euronext group. This transformational project would effectively position the newly formed group to deliver the ambition of further building the backbone of the Capital Markets Union in Europe, while at the same time supporting local economies.A further announcement will be made as and when appropriate.CONTACTS...

Celyad Oncology Establishes At-the-Market Facility

Written by Customer Service on September 14, 2020. Posted in Public Companies.

MONT-SAINT-GUIBERT, Belgium, Sept. 14, 2020 (GLOBE NEWSWIRE) — Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that it has entered into an Open Market Sale AgreementSM with Jefferies LLC (“Jefferies”) pursuant to which the Company may from time to time sell, for a period of up to 36 months, through “an at the market offering” (“ATM”), with Jefferies acting as sales agent, up to $25,000,000 of new American Depositary Shares (“ADSs”), each of which represents one ordinary share of the Company, assuming sales of 2,522,704 ADSs in the offering at an offering price of $9.91 per ADS, which was the last reported sale price of the ADSs on the Nasdaq Global Market on September...

Kiadis announces U.S. FDA approval of the Abigail Wexner Research Institute at Nationwide Children’s Hospital’s IND for a COVID-19 clinical trial with off-the-shelf K-NK cells using Kiadis’ proprietary platforms

Written by Customer Service on September 14, 2020. Posted in Public Companies.

Amsterdam, The Netherlands, September 14, 2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company developing innovative cell-based medicines for the treatment of life-threatening diseases, today announces a collaboration with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital to develop Kiadis-NK cells (K-NK cells) as a post-exposure pre-emptive therapy for COVID-19. The U.S. Food and Drug Administration (FDA) approved AWRI’s investigational new drug application (IND) for a study in an adult population with off-the-shelf natural killer (NK) cells produced with Kiadis’ proprietary Universal Donor and PM21 technologies. Kiadis and AWRI are developing the plan for initiation of the clinical study.Kiadis has exclusively licensed from...

FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

Written by Customer Service on September 14, 2020. Posted in Public Companies.

FDA grants Dupixent® (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitisDesignation based on positive results from Part A of pivotal Phase 3 trialDupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE)There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients’ ability to swallow and eatDesignation supports Dupixent’s potential in another disease driven by type 2 inflammationPARIS and TARRYTOWN, N.Y., September 14, 2020 – The U.S. Food and Drug Administration (FDA) has granted...

Month: September 2020

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals